Date: 2018-01-04
Type of information: Licensing agreement
Compound: F17727
Company: Pierre Fabre (France) Boston Pharmaceuticals (USA - MA)
Therapeutic area: Cardiovascular diseases
Type agreement: licensing
Action mechanism: potassium channel blocker
Disease: atrial fibrillation
Details:
- • On January 4, 2018, Pierre Fabre and Boston Pharmaceuticals announced they have entered into a worldwide licensing agreement for Pierre Fabre's selective potassium channel blocker, F17727. F17727 is a small molecule in late preclinical development for the potential treatment of atrial fibrillation. Under the terms of the agreement, Pierre Fabre grants Boston Pharmaceuticals worldwide exclusive rights for the development, manufacturing and commercialization of F17727.
Financial terms:
- Financial terms of the agreement were not disclosed.
Latest news:
Is general: Yes
